the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
The drug retention rate of vedolizumab for ulcerative colitis decreases with time. This study analyzed the long-term drug retention rate and its influencing factors in patients with moderately to severely active ulcerative colitis treated with vedolizumab.
Epistemonikos ID: 3b36f58d46bb167ccdde85fbb633b7e15609dcbd
First added on: Mar 27, 2025